文献速递甲状腺疾病

下一代测序在晚期甲状腺癌中的临床应用

Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers.
PubMed 文献 · Thyroid · 2022-05-16

本研究纳入118例在玛格丽特公主癌症中心参加IMPACT或OCTANE临床试验并完成NGS的晚期甲状腺癌患者,回顾病历并按OncoKB框架评估可操作性。87%患者存在可操作变异,57%存在至少一个Level 1或2变异,13%接受了匹配治疗。作者认为该结果支持晚期甲状腺癌管理中常规多基因NGS检测或反射性BRAF和RET检测。

要点

  • 118例晚期甲状腺癌患者中87%存在可操作变异,57%有至少一个Level 1或2变异。
  • BRAF和RET变异占Level 1和2变异的86%。
  • 仅13%患者接受了针对可操作变异的匹配治疗。

核心结论

  • 大多数晚期甲状腺癌患者至少有一个潜在可操作变异,57%患者有至少一个Level 1或2变异,主要由BRAF V600E和RET变异驱动。
  • 作者认为本研究结果支持在晚期甲状腺癌患者管理中常规进行多基因NGS检测或反射性BRAF和RET检测。

研究设计与样本

  • 纳入在玛格丽特公主癌症中心参加IMPACT(NCT01505400)或OCTANE(NCT02906943)临床试验并完成NGS的晚期甲状腺癌患者,共118例,NGS检测于2013年至2020年间完成。
  • 回顾电子病历收集临床病理和治疗数据,采用OncoKB框架按可操作性水平对分子变异进行分类。
  • OncoKB框架判定为可操作变异且接受了针对该变异靶向药物治疗的患者归为接受「匹配」治疗。
  • 时间-事件数据采用Kaplan-Meier法分析。
  • 研究经大学健康网络研究伦理委员会批准(ID# 19-5888)。

主要发现

  • 甲状腺乳头状癌中最常见的分子变异为BRAF V600E(62%)和NRAS(15%)突变。
  • 甲状腺髓样癌中RET变异占78%。
  • 甲状腺未分化癌中BRAF V600E突变占38%,TP53突变占62%。
  • 87%患者存在可操作变异,57%患者有至少一个Level 1或2变异且有FDA批准药物可用。
  • BRAF和RET变异占Level 1和2变异的86%,13%患者接受了匹配治疗。

关键数值与推荐

  • 可操作变异按OncoKB框架分级,Level 1或2定义为有FDA批准药物可用的变异。
  • 匹配治疗定义为OncoKB框架判定为可操作变异且接受针对该变异靶向药物的治疗。

临床怎么用

  • 作者认为本研究结果支持在晚期甲状腺癌患者管理中常规进行多基因NGS检测或反射性BRAF和RET检测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: With the emergence of mutation-based systemic therapies for patients with advanced thyroid cancer, molecular profiling has become an important component of care. Although next-generation sequencing (NGS) gene panels are accessible to clinicians, there is no consensus on the optimal approach to testing. This study investigates the clinical application of NGS results in the management of advanced thyroid cancer. Methods: Patients with advanced thyroid cancer with NGS completed as part of the Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT; NCT01505400) or Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE; NCT02906943) clinical trials at the Princess Margaret Cancer Centre were included. Electronic medical records were reviewed to collect clinicopathologic and treatment data. The OncoKB framework was used to categorize molecular alterations based on levels of actionability. Patients with an actionable alteration by OncoKB framework who had treatment with a drug targeting the alteration were categorized as receiving "matched" therapy. Time-to-event data were analyzed using the Kaplan-Meier method. This study was approved by the University Health Network Research Ethics Board (ID# 19-5888). Results: NGS was performed on 118 patients with advanced thyroid cancer between 2013 and 2020. The most common molecular alterations included BRAF V600E (62%) and NRAS (15%) mutations in papillary thyroid cancer, RET alterations (78%) in medullary thyroid cancer, and BRAF V600E (38%) and TP53 (62%) mutations in anaplastic thyroid cancer. Actionable alterations were found in 87% of patients, and 57% of patients had at least one Level 1 or 2 alteration for which Food and Drug Administration (FDA)-approved drug is available. BRAF and RET alterations made up 86% of Level 1 and 2 alterations. A matched therapeutic approach was undertaken in 13% of patients. Conclusion: This study uses a structured framework to analyze the actionability and clinical use of NGS results in advanced thyroid cancer. Most patients had at least one potentially actionable mutation and 57% of patients had at least one Level 1 or 2 alteration, predominantly driven by BRAF V600E and RET alterations. This study rationalizes the need for routine multigene NGS testing or reflex BRAF and RET testing in the management of patients with advanced thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ma LX, Espin-Garcia O, Bedard PL, et al. Clinical Application of Next-Generation Sequencing in Advanced Thyroid Cancers. Thyroid. 2022. PMID: 35262412. doi:10.1089/thy.2021.0542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。